Applied Therapeutics Q4 2023 Earnings Report

Applied Therapeutics EPS Results

• Actual EPS: -$0.33
• Consensus EPS: -$0.15
• Beat/Miss: Missed by -$0.18
• One Year Ago EPS: N/A

Applied Therapeutics Revenue Results

• Actual Revenue: ($0.67) million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Applied Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/6/2024
• Time: N/A
• Conference Call Date: Wednesday, March 6, 2024
• Conference Call Time: 7:00AM ET

Applied Therapeutics (NASDAQ:APLT) is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel therapeutics that address the underlying causes of serious diseases. The company’s research focuses on metabolic and renal indications, aiming to bring differentiated treatments to patients with high unmet medical needs. Applied Therapeutics leverages a deep understanding of human biology and a precision medicine approach to identify targets that can modulate disease pathways and deliver meaningful clinical benefits.

The company’s most advanced program targets mitochondrial dysfunction and impaired energy metabolism with its investigational small molecule, beraprost sodium. Initially developed as a prostacyclin analogue, beraprost is being repositioned by Applied Therapeutics to explore new indications in rare metabolic disorders and chronic kidney disease. In addition to beraprost, the company’s pipeline includes small molecules designed to restore cellular homeostasis by enhancing nicotinamide adenine dinucleotide (NAD+) levels. These programs are supported by preclinical and early‐stage clinical studies that aim to validate mechanisms of action and demonstrate safety and efficacy in targeted patient populations.

Applied Therapeutics was founded in 2018 and is headquartered in New York City. Since its inception, the company has built a specialized team of drug discovery scientists, clinical development experts, and regulatory professionals. Applied Therapeutics collaborates with academic institutions and biotech partners to accelerate the translation of its research into clinical milestones. The company’s strategic alliances and in-licensing agreements have expanded its capabilities in medicinal chemistry, preclinical toxicology, and clinical trial execution.

Under the leadership of President and Chief Executive Officer James (“Jim”) McArthur, Applied Therapeutics has advanced from an early research outfit to a publicly traded biotech firm listed on the Nasdaq exchange. The management team includes seasoned executives with prior experience at leading pharmaceutical and biotechnology companies, providing strong governance and operational expertise. As Applied Therapeutics progresses its clinical programs, the company remains committed to delivering innovative therapies that improve patient outcomes in metabolic and renal diseases worldwide.